ST九芝最新公告：沃拉德单抗注射液在国内启动临床试验

证券之星11-01

ST九芝公告，参股公司科信美德与母公司美国瑞美德生物医药公司研发的针对胰高血糖素受体的1类创新药沃拉德单抗注射液，获得国家药品监督管理局的“药物临床试验批准证书”，同意本品在中国1型糖尿病患者中开展临床试验。

以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2480000594?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-01 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480000594","market":"hk","top_or_hot":-1,"title":"ST九芝最新公告：沃拉德单抗注射液在国内启动临床试验","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/000989\">ST九芝</a>公告，参股公司科信美德与母公司美国瑞美德生物医药公司研发的针对胰高血糖素受体的1类创新药沃拉德单抗注射液，获得国家药品监督管理局的“药物临床试验批准证书”，同意本品在中国1型糖尿病患者中开展临床试验。</p><p>以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST九芝最新公告：沃拉德单抗注射液在国内启动临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST九芝最新公告：沃拉德单抗注射液在国内启动临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 20:25 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2024110100044382.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ST九芝公告，参股公司科信美德与母公司美国瑞美德生物医药公司研发的针对胰高血糖素受体的1类创新药沃拉德单抗注射液，获得国家药品监督管理局的“药物临床试验批准证书”，同意本品在中国1型糖尿病患者中开展临床试验。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。</p>\n\n<a href=\"https://stock.stockstar.com/RB2024110100044382.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"000989","symbol_name":"ST九芝","start_time":0,"source_url":"https://stock.stockstar.com/RB2024110100044382.shtml","article_id":"2480000594","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480000594","pubTimestamp":1730463916,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"ST九芝公告，参股公司科信美德与母公司美国瑞美德生物医药公司研发的针对胰高血糖素受体的1类创新药沃拉德单抗注射液，获得国家药品监督管理局的“药物临床试验批准证书”，同意本品在中国1型糖尿病患者中开展临床试验。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"000989":"ST九芝","BK0185":"二线龙头","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","BK0188":"融资融券","03347":"泰格医药","BK1583":"高瓴概念","BK0239":"医药制造"},"translate_title":"ST Jiuzhi's latest announcement: Voladumab injection starts clinical trials in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000989":1,"03347":1},"content_text":"ST九芝公告，参股公司科信美德与母公司美国瑞美德生物医药公司研发的针对胰高血糖素受体的1类创新药沃拉德单抗注射液，获得国家药品监督管理局的“药物临床试验批准证书”，同意本品在中国1型糖尿病患者中开展临床试验。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480000594"}